227 abstracts found.



Results filter



We need to talk about clonal diversity

Year:

Session type:

Mel Greaves1

1The Institute of Cancer Research, London, UK




Treatment-induced pain in cancer patients

Year:

Session type:

Patrick Dougherty1
1The University of Texas MD Anderson Cancer Center, Houston, USA



Within-tumour diversity as a universal biomarker of prognosis

Year:

Session type:

Trevor Graham1
1Barts Cancer Institute, London, UK



Update on targeted treatments for painful neuropathy

Year:

Session type:

Marie Fallon1
1IGMM Edinburgh Cancer Research Centre



Imaging tumour heterogeneity

Year:

Session type:

Robert J Gillies1
1H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA



Epidemiology and risk factors for persistent pain after breast cancer surgery

Year:

Session type:

Julie Bruce1
1University of Warwick, Coventry, UK



Clinical decision support systems

Year:

Session type:

Willie Hamilton1
1Peninsula College of Medicine and Dentistry, Exeter, UK



Clinical decision support systems: Some core concepts and questions

Year:

Session type:

Jeremy C Wyatt1
1Institute of Health Sciences, Leeds, UK



Computer based clinical decision support systems (CDSSs) utilising clinical prediction rules (CPRs) as part of referral for cancer

Year:

Session type:

Tom Fahey1
1HRB Centre for Primary Care Research, Dublin, Ireland



Practical implementation of cancer clinical decision support

Year:

Session type:

Willie Hamilton1
1University of Exeter Medical School, Exeter, UK



Introduction: Latest developments in radiotherapy for breast cancer

Year:

Session type:

Alastair M Thompson1
1Dundee Cancer Centre, UK



The 2013 George Edelstyn Lecture: The long and the short of radiotherapy fractionation in early breast cancer

Year:

Session type:

John Yarnold1
1The Institute of Cancer Research, London, UK



Should all breast radiotherapy be delivered with intensity modulated radiotherapy (IMRT)?

Year:

Session type:

Charlotte Coles1
1Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK



How can we reduce cardiac risk for women with left breast cancer?

Year:

Session type:

Anna M Kirby1
1The Royal Marsden NHS Foundation Trust, London, UK



Computational models to predict and dissect mechanistically drug sensitivity in cancer

Year:

Session type:

Julio Saez-Rodriguez1
1European Bioinformatics Institute EMBL-EBI, Cambridge, UK



Can computation help cure cancer?

Year:

Session type:

Jasmin Fisher1
1Microsoft Research Cambridge and University of Cambridge, Cambridge, UK



New methods for tumour functional imaging

Year:

Session type:

Kevin Brindle1
1University of Cambridge and Cancer Research UK Cambridge Institute, UK



From functional genomics to executable cancer biology

Year:

Session type:

Jasmin Fisher1
1Microsoft Research Cambridge, Cambridge, UK



Transcriptional network control of normal and leukaemic blood stem/progenitor cells

Year:

Session type:

Bertie Gottgens1
1University of Cambridge, Cambridge, UK



Models for delivery of follow-up care – what does the evidence tell us thus far?

Year:

Session type:

Jon Emery1

1University of Melbourne, Melbourne, Australia




Optimising care beyond breast cancer – perspectives from the front line

Year:

Session type:

Alastair M Thompson1, Maggie Wilcox2
1University of Texas MD Anderson Cancer Center, Houston, USA,2Independent Cancer Patients' Voice, London, UK



Unravelling the complexity of lung cancer evolution

Year:

Session type:

Nicholas McGranahan1
1CR-UK London Research Institute, London, UK



Computational dissection of intratumour genetic heterogeneity and applications to the study of cancer treatment, evolution and metastasis

Year:

Session type:

Scott Carter1,2
1Broad Institute of MIT-Harvard, Cambridge, MA, USA,2Dana-Farber Cancer Institute, Boston, MA, USA,3Massachusetts General Hospital, Boston, MA, USA



What can we learn from circulating tumour cells in lung cancer – biomarkers, mouse models, drug resistance and heterogeneity

Year:

Session type:

Caroline Dive1
1Cancer Research UK Manchester Institute, Manchester, UK



Introduction: Cancer immunotherapy 2014: a new paradigm

Year:

Session type:

James Larkin1
1The Royal Marsden NHS Foundation Trust, London, UK



Introduction: Inflammation and cancer

Year:

Session type:

Fran Balkwill1
1Queen Mary, University of London, London, UK



T cell checkpoint blockade in melanoma: from mouse to man and back

Year:

Session type:

Christian Blank1
1The Netherlands Cancer Institute, Amsterdam, The Netherlands



The targets for tumour immunotherapy mediated by the inflammatory properties of vesicular stomatitis virus (VSV)-based antigen presentation depend upon the tumour’s anatomical site

Year:

Session type:

Richard Vile1
1Mayo Clinic, Rochester, USA



Targeting immune checkpoints in cancer: new mechanistic insights

Year:

Session type:

Sergio A Quezada1
1UCL Cancer Institute, University College London, London, UK



Co-targeting angiogenesis and immunosuppressive cell networks to improve anti-cancer therapy

Year:

Session type:

Michele De Palma1
The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland (1)



T cell immunosurveillance of healthy and transformed epithelia

Year:

Session type:

Adrian Hayday1
1King's College London, London, UK



Neutrophil-derived signals promote initiation abilities of cancer stem cells during metastasis

Year:

Session type:

Ilaria Malanchi1
1Cancer Research UK, London, UK



Introduction: High precision radiation therapy

Year:

Session type:

Diana Tait1
1The Royal Marsden NHS Foundation Trust and The Royal College of Radiologists, London, UK



Progress in breast cancer prevention

Year:

Session type:

Jack Cuzick1
1Queen Mary, University of London, London, UK



Stereotactic ablative radiotherapy (SABR): a local therapy poised to fight metastatic cancer

Year:

Session type:

Robert Timmerman1
1University of Texas Southwestern Medical Center, Dallas, USA



Effects of aspirin on cancer incidence and metastasis

Year:

Session type:

Peter M Rothwell1
1University of Oxford, Oxford, UK



Proton therapy: pushing the frontiers of radiotherapy

Year:

Session type:

Tony Lomax1
1Centre for Proton Therapy, Paul Scherrer Institut, Villigen, Switzerland



Cancer and obesity prevention: finding the causes of the causes

Year:

Session type:

Tim Lobstein1,2
1World Obesity Federation, London, UK,2Curtin University, Perth, Australia



Image guided radiation therapy

Year:

Session type:

Uwe Oelfke1
1The Institute of Cancer Research UK and The Royal Marsden NHS Foundation Trust, London, UK



Introduction: Stem cells and cancer

Year:

Session type:

Axel Behrens1
1ancer Research UK London Research Institute, London, UK



Introduction: Optimising care for those living with and beyond cancer – where does primary care fit in?

Year:

Session type:

Eila Watson1
1Oxford Brookes University, UK, Oxford, UK



Wnt activating mechanisms in colorectal cancer

Year:

Session type:

Vivian Li1
1Medical Research Council (MRC) National Institute for Medical Research, London, UK



Primary care views on optimising care for those living with and beyond cancer: findings from a systematic review and GP survey

Year:

Session type:

Fiona Walter1
1University of Cambridge, Cambridge, UK



Tumour-propagating cells in non-small cell lung cancer

Year:

Session type:

Carla Kim1
1Children's Hospital Boston, Boston, USA



Neutral and biased replacement of intestinal stem cells

Year:

Session type:

Doug Winton1
1Cancer Research UK Cambridge Institute, Cambridge, UK



Introduction: Cancer evolution

Year:

Session type:

Charles Swanton1,2
1Cancer Research UK London Research Institute, London, UK,2niversity College London Cancer Institute, London, UK



Making sense of intratumour heterogeneity: evidence of a ‘Big Bang’ tumour expansion

Year:

Session type:

Andrea Sottoriva1
1The Institute of Cancer Research, London, UK



Molecular profiling of single circulating tumour cells with diagnostic intention

Year:

Session type:

Christoph Klein1,2
1University of Regensburg, Regensburg, Germany,2Fraunhofer Project Group, ITEM-Regensburg, Germany



Circulating cell-free DNA as a strong multimarker diagnostic, theranostic and prognostic tool for metastatic colorectal cancer patients management care

Year:

Session type:

Alain R Thierry1
1French Institute of Health and Medical Research (INSERM), Montpellier, France



Introduction: Circulating biomarkers: where have we got to and what’s on the horizon?

Year:

Session type:

Caroline Dive1
1Cancer Research UK, Manchester, UK